Rehmann Capital Advisory Group’s NovoCure NVCR Stock Holding History

Rehmann Capital Advisory Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$3.66K	Sell	49 -9,432	-99%	-$754K	﹤0.01%	1291
2019 Q2	$599K	Buy	9,481 +9,432	+19,249%	+$478K	0.07%	214
2019 Q1	$2.36K	Hold	49	–	–	﹤0.01%	1716
2018 Q4	$1.64K	Sell	49 -50	-51%	-$1.83K	﹤0.01%	1517
2018 Q3	$5.19K	Buy	99 +50	+102%	+$1.99K	﹤0.01%	1553
2018 Q2	$1.53K	Buy	+49	New	+$1.36K	﹤0.01%	1868

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rehmann Capital Advisory Group's NVCR Position: Q3 2019 in Review

Rehmann Capital Advisory Group reduced its NovoCure (NVCR) stake by 99% in Q3 2019, selling an estimated $754K and leaving 49 shares worth $3.66K. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Rehmann Capital Advisory Group first reported a position in NVCR in Q2 2018 and has held it in 6 quarters since. The position peaked at $599K in Q2 2019. 240 funds tracked by Wall St. Rank hold NVCR as of Q3 2019.

Rehmann Capital Advisory Group held 49 shares of NovoCure worth $3.66K as of Q3 2019.
Rehmann Capital Advisory Group sold 9,432 NovoCure shares in Q3 2019, an estimated $754K.
NovoCure made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1291 holding.
Rehmann Capital Advisory Group first reported a position in NovoCure in Q2 2018 and has held it in 6 quarters since.
Rehmann Capital Advisory Group's NovoCure position peaked at $599K in Q2 2019.
240 funds tracked by Wall St. Rank held NovoCure as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.